FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology for the ablation of cancer and other chronic health conditions, today announced that it has entered into a distribution agreement with Aesculap, Inc., a subsidiary of B. Braun, for the domestic distribution of the Misonix BoneScalpel™, a new Ultrasonic Osteotome (or bone cutting device) for use in orthopedic and neurological applications related to the spine and cranium. Misonix previously received Food and Drug Administration clearance to market its Ultrasonic Osteotome medical devices. The agreement provides Aesculap with the right to sell in the United States and includes minimum purchase requirements and the payment of a royalty on sales of disposables.
